Swedish Orphan Biovitrum AB (0MTD) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Swedish Orphan Biovitrum AB SEK 909, price SEK 430, upside +111.3%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care.
Show more
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Stock analysis
Swedish Orphan Biovitrum AB (0MTD) currently trades at kr 430.10, while our model-based Fair Value estimate is kr 908.62, implying the stock looks roughly 52.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 871.72 per share, and 14 of the 23 models we run sit above the kr 430.10 price.
Bear case: the Asset-Based group reads lowest at kr 101.55, and 9 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: kr 472.00 (bear) to kr 1,181 (bull), the price of kr 430.10 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Swedish Orphan Biovitrum AB reported revenue of 15.3B SEK in FY2020 versus 5.2B SEK in FY2016, a compound +30.9%/yr. Reported net income was 3.2B SEK in FY2020, compounding +41.9%/yr from FY2016. FY2016 was a trough year, so the rate overstates the trend.
Key figures
Market cap 57.3B SEK (≈ $5.7B) · P/S ratio 1.87 · Net margin 21.3% · Return on equity 3.4% · Return on assets (EBIT) 12.8% · Operating margin 25.3% · Revenue (TTM) 30.6B SEK · Revenue growth (YoY) +27.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −34% fair-value upside, at 111%, 0MTD screens cheaper than that median.
Fair Value models
Bear kr 472.00Fair Value kr 908.62Bull kr 1,181
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.8%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.8% (2016) → 31.6% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Swedish Orphan Biovitrum AB Fair Value". https://www.fairvalue-calculator.com/stock/0MTD
Frequently asked questions
Is Swedish Orphan Biovitrum AB (0MTD) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 908.62 versus a price of kr 430.10, about +111% upside (undervalued).
What is the fair value of 0MTD?
Our model-based fair value for Swedish Orphan Biovitrum AB is kr 908.62 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 430.10.
What is the quality score of 0MTD?
Swedish Orphan Biovitrum AB has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Swedish Orphan Biovitrum AB (0MTD)?
Our model-based price target is the fair value of kr 908.62 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario kr 472.00, optimistic scenario kr 1,181. It is a calculation from audited fundamentals, not an analyst target.
What is the Swedish Orphan Biovitrum AB stock forecast for 2026?
Our models put fair value at kr 908.62, about +111% upside versus a price of kr 430.10 (undervalued). Cautious scenario kr 472.00, optimistic scenario kr 1,181. The calculation is refreshed regularly with new filings.
What is the revenue of Swedish Orphan Biovitrum AB (0MTD)?
Swedish Orphan Biovitrum AB reported trailing-twelve-month revenue of about 30.6B SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Swedish Orphan Biovitrum AB (0MTD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Swedish Orphan Biovitrum AB it is kr 908.62 per share (as of Sep 24, 2026), against a price of kr 430.10. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Swedish Orphan Biovitrum AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0MTD trades below its calculated fair value: price kr 430.10, fair value kr 908.62, a gap of about +111% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0MTD?
No. The price is what the market pays today (kr 430.10); the fair value is what the company's own numbers justify (kr 908.62). For Swedish Orphan Biovitrum AB the two are kr 478.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is Swedish Orphan Biovitrum AB worth?
The market values Swedish Orphan Biovitrum AB at about 57.3B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 430.10; our models calculate a fair value of kr 908.62 per share.
What do the bullish and bearish scenarios say about 0MTD?
Our models span a range for Swedish Orphan Biovitrum AB: cautious scenario kr 472.00, base kr 908.62, optimistic kr 1,181 per share (as of Sep 24, 2026, price kr 430.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0MTD from its 52-week high?
Swedish Orphan Biovitrum AB trades at kr 430.10, about 11% below its 52-week high of kr 482.70 and 46% above the low of kr 295.00 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 908.62 is for.
Which stocks are comparable to Swedish Orphan Biovitrum AB?
From the same area (Industrials) we also value AEPL, COSPOWER, PANAENERG, LAKSELEC, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Swedish Orphan Biovitrum AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 430.10, calculated fair value kr 908.62 (+111%), Quality Score 53/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0MTD calculated?
We run Swedish Orphan Biovitrum AB through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 908.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Swedish Orphan Biovitrum AB currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Swedish Orphan Biovitrum AB (0MTD)?
The closing price on Oct 2, 2026 was kr 430.10. Our model-based fair value is kr 908.62, about +111% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Swedish Orphan Biovitrum AB right now?
The price is below even our cautious bear case (kr 472.00). The market is more pessimistic than our downside scenario. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (kr 472.00 to kr 1,181) leaves room in how you read the outcome.
Key figures of Swedish Orphan Biovitrum AB
How large is the market capitalisation of Swedish Orphan Biovitrum AB (0MTD)?
The market capitalisation of Swedish Orphan Biovitrum AB is 57.3B SEK (≈ $5.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Swedish Orphan Biovitrum AB (0MTD)?
The price-to-sales ratio of Swedish Orphan Biovitrum AB is 1.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Swedish Orphan Biovitrum AB (0MTD)?
The net margin of Swedish Orphan Biovitrum AB is 21.3% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Swedish Orphan Biovitrum AB (0MTD)?
The return on equity (ROE) of Swedish Orphan Biovitrum AB is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Swedish Orphan Biovitrum AB (0MTD)?
On an EBIT basis the return on assets of Swedish Orphan Biovitrum AB is 12.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Swedish Orphan Biovitrum AB (0MTD)?
The operating margin of Swedish Orphan Biovitrum AB is 25.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Swedish Orphan Biovitrum AB (0MTD)?
Revenue at Swedish Orphan Biovitrum AB is growing +27.0% versus a year earlier (3y avg +32.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Swedish Orphan Biovitrum AB (0MTD)?
Earnings per share at Swedish Orphan Biovitrum AB are growing +71.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
